Press Releases

DarioHealth to Offer Diabetes Content and Coaching to Patients in Canada in Collaboration With LMC Healthcare, Canada's Largest Diabetes and Endocrinology Specialist Care Provider

DarioHealth's Digital Diabetes Content and Coaching, powered by LMC, to be made available across Canada starting in Q12019

Dec 12, 2018

CAESAREA, Israel, Dec. 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Toronto-based LMC Healthcare, Canada's largest specialist care provider in diabetes and endocrinology, will work with Dario who will provide digital content and coaching services  across Canada for patients with diabetes. LMC has 11 clinics and 19 clinical research sites that provide care to over 39,000 patients with diabetes in Canada.

DarioHealth Logo (PRNewsfoto/DarioHealth Corp.)

To power the Dario Digital Content and Coaching offering, LMC will have dedicated diabetes coaches who will leverage the DarioEngage platform to communicate with patients. The full suite of DarioEngage features will be made available to all DarioHealth consumers across Canada.

LMC Healthcare President and CEO, Mark Angelo, commented, "We are very excited to expand LMC's reach by offering a digital diabetes education program through the DarioEngage platform. LMC is dedicated to transforming diabetes specialist care by making it more accessible, comprehensive and patient-centric than ever before and we believe DarioEngage will support us in this mission, across Canada."

Olivier Jarry, President and Chief Commercial Officer of DarioHealth added, "We are very pleased to partner with LMC, the leader in diabetes healthcare in one of the world's most advanced healthcare markets. DarioEngage was developed to seamlessly integrate with healthcare service providers' internal systems. It is a scalable and turnkey solution that delivers the advantages of digital healthcare to a growing number of organizations."

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit

About LMC Healthcare

LMC Healthcare is Canada's largest specialist care provider in diabetes & endocrinology and represents one of the largest endocrinology groups in the world. LMC is committed to transforming diabetes specialist care by making it more accessible, comprehensive and patient-centric than ever before.  LMC brings a multidisciplinary approach, offering multiple diabetes-related services under one roof, including diabetes specialist care, diabetes education, foot specialist care, optometry, diabetes pharmacy and clinical research. LMC's goal is to "Make Healthy Easier" for its patients by providing them with the tools and resources they need to better manage their health so they can lead full and happy lives. For more information, visit

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes its plan to enroll a few thousand patients in the next 4 quarters, while longer term, DarioEngage will be made available to all DarioHealth consumers across Canada, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact: 

Joao Mendes-Roter, VP Marketing,, 1-347-767-4220


SOURCE DarioHealth Corp.